Credit Agricole
CRSP icon

Credit Agricole’s CRISPR Therapeutics CRSP Stock Holding History

Credit Agricole’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.69M Buy
+85,930
New +$4.53M 0.01% 718
2025
Q1 		$44.2K Hold
1,300
– – ﹤0.01% 1167
2024
Q4 		$51.2K Hold
1,300
– – ﹤0.01% 1181
2024
Q3 		$61.1K Hold
1,300
– – ﹤0.01% 1139
2024
Q2 		$70.2K Hold
1,300
– – ﹤0.01% 982
2024
Q1 		$73K Hold
1,300
– – ﹤0.01% 774
2023
Q4 		$81.4K Hold
1,300
– – ﹤0.01% 759
2023
Q3 		$59K Hold
1,300
– – ﹤0.01% 774
2023
Q2 		$73K Hold
1,300
– – ﹤0.01% 501
2023
Q1 		$58.8K Hold
1,300
– – ﹤0.01% 491
2022
Q4 		$52.8K Hold
1,300
– – ﹤0.01% 521
2022
Q3 		$85K Hold
1,300
– – ﹤0.01% 469
2022
Q2 		$79K Sell
1,300
-100
-7% -$5.88K ﹤0.01% 476
2022
Q1 		$88K Sell
1,400
-5,200
-79% -$327K ﹤0.01% 485
2021
Q4 		$500K Buy
6,600
+5,000
+313% +$437K 0.01% 345
2021
Q3 		$179K Buy
+1,600
New +$201K ﹤0.01% 395

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Credit Agricole's CRSP Position: Q2 2026 in Review

Credit Agricole opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 85,930 shares worth $4.69M. The stake represents 0.01% of the portfolio and ranks #718 among its holdings. This is a return to the name: Credit Agricole previously reported a position in CRSP as recently as Q1 2025.

Credit Agricole first reported a position in CRSP in Q3 2021 and has held it in 16 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Credit Agricole held 85,930 shares of CRISPR Therapeutics worth $4.69M as of Q2 2026.
  • CRISPR Therapeutics was a new Credit Agricole position in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Credit Agricole's portfolio in Q2 2026, its #718 holding.
  • Credit Agricole first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Credit Agricole's 13F filing for Q2 2026, filed 14 Aug 2026.